**Study Summary** This study is testing a new treatment called APL-3007 combined with another treatment, Syfovre/Pegcetacoplan (APL-2), for people with a specific eye condition called Geographic Atrophy (GA), which is a part of Age-Related Macular Degeneration (AMD). This is a Phase 2 study, meaning researchers have already done some testing and are now checking how well the treatment works and how safe it is. Participants must be 60 years or older and have GA in at least one eye. They must also have received previous treatment with Syfovre for their condition. **Key Points:** - **Duration & Visits:** Participants will be part of a longer-term study, with multiple visits over time. - **Eligibility:** Must have GA due to AMD, be 60+, and meet other health criteria. - **Compensation:** Participants may receive compensation for their time and travel. If you have this eye condition and meet the criteria, you might consider joining to help research new treatments. Always discuss with your doctor before participating.